VONTROL
LOE ApproachingNDAORALTABLET
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VONTROL is an oral small-molecule tablet approved by GSK in 1967 for an undisclosed indication. The mechanism of action and pharmacologic class are not specified in available data. As a legacy NDA product, VONTROL represents a mature marketed asset in GSK's portfolio.
LOE Approaching
Product is in LOE-approaching phase with moderate competitive pressure (30%), signaling potential restructuring or winddown of the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for VONTROL roles. This product offers limited career growth opportunity and suggests positions would focus on defending market share during LOE transition rather than expansion.
Brand ManagerField Sales Representative
Worked on VONTROL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.